Investindustrial-backed Universal Clinics, a clinics operator, and EQT-backed Igenomix, a firm engaged in genetic testing, agreed to form Novalbufera, a joint venture that aims to develop and commercialize a medical device for embryo culture in fertility laboratories. Financial terms were not disclosed. The new company, called Novalbufera, will be owned by Igenomix and Universal Clinics. Both funds entered the assisted reproduction sector in Spain almost simultaneously in 2019. This acquisition was the first step in the creation of the GeneraLife platform, which has grown through other purchases by companies in the sector in Italy, the Czech Republic and Sweden. Currently, this platform offers about 15k treatments a year and has a staff of 350 doctors.